阿德福韦酯联合拉米夫定治疗HBV-YMDD变异  

Theraputic effect and safety of lamivudine combined with adefovir dipivoxil treatment in hepatitis B of HBV-YMDD

作　　者：邹桂舟[1] 郜玉峰[1] 叶珺[1] 

机构地区：[1]安徽医科大学附属第二医院肝病科,合肥230601

出　　处：《安徽医学》2012年第2期150-152,共3页Anhui Medical Journal

基　　金：安徽省卫生厅基金项目(编号:09A063)

摘　　要：目的比较阿德福韦酯联合拉米夫定和单用阿德福韦酯治疗YMDD变异的慢性乙型肝炎的疗效和安全性。方法将112例在拉米夫定治疗过程中出现YMDD变异的慢性乙型肝炎患者随机分为两组(各56例),治疗组:继续接受拉米夫定100mg/d治疗,全程联合阿德福韦酯10 mg/d;对照组:拉米夫定100 mg/d和阿德福韦酯10 mg/d联合治疗12周后单用阿德福韦酯10mg/d,疗程96周。结果两组患者治疗后ALT、AST水平均较治疗前显著改善(P<0.05);治疗组治疗48周,96周时肝功能ALT、AST改善优于对照组(P<0.05);HBV DNA转阴率显著高于对照组(P<0.05)。结论阿德福韦酯对YMDD变异的慢性乙型肝炎患者有良好的疗效和安全性,联合拉米夫定临床疗效更显著。Objective To evaluate the clinical efficacy and safety of lamivudine（LAM）combined with adefovirdipivoxil（ADV）in treating hepatitis B of HBV-YMDDMethods 112 patients with HBV-YMDD of chronic hepatitis B were randomly divided into the treated group who were given LAM combined with ADV and control group who were only given ADV after LAM combined with ADV in first 12 weeks.The patients in both groups were followed-up for 96 weeks.Results Their liver founction tests improved in two group at the end of treatment;The effects in treated group was superior to those in control group after 48 and 96 weeks treatment.No obvious adverse reactions was found in patients who took the medicine.Conclusion ADV combined with LAM have better clinical efficacy and safety in patients of hepatitis B of HBV-YMDD.LAM combined with ADV was superior to those in ADV only.

关 键 词：慢性乙型肝炎 YMDD变异 阿德福韦酯 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]